secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0000950170-25-111586
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud

MannKind receives $5M upfront from United Therapeutics for new product option exercise
--------------------------------------------------------------------------------

- MannKind entered First Amendment with United Therapeutics to exercise option for an additional development product using its Technosphere platform.
- MannKind receives $5M upfront payment and is eligible for up to $35M in milestone payments.
- MannKind will manufacture clinical trial materials; United Therapeutics will conduct all other preclinical and clinical development.
- MannKind will earn 10% royalties on net sales of the additional product if approved.
- United Therapeutics exercised withdrawal option retains right to withdraw the exercise for the new agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000095017025111586/0000950170-25-111586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000095017025111586/mnkd-20250824.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-111586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer